CROs

Scale Inclusive Enrollment with Confidence

CROs choose Acclinate because they need consistency, predictability, and operational efficiency across every site and every trial.

Schedule a Strategy Session

Solution

Acclinate

Platform for Operational Excellence

We offer the tools to standardize your diversity efforts across your entire portfolio, moving from chaos to quantifiable control.

The Challenge

Sourcing diverse participants and managing site readiness across decentralized trials introduces costly bottlenecks and unpredictable outcomes.

Your success relies on providing sponsors with consistent, scalable, and measurable results.

Use Cases

Our Solution Stack

Reliable Participant Flow

Ensure scalable sourcing with NOWINCLUDED, guaranteeing engagement KPIs that surpass traditional recruitment methods.

Standardized Site Vetting

Eliminate site inconsistency by implementing the e-SITE assessment across your network to rapidly identify and optimize sites for diversity readiness before activation.

Centralized Tracking

Streamline reporting by utilizing e-DICT, which offers a single, centralized view of all engagement metrics and referral funnels across your trials.

Predictive Enrollment Intelligence

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis.

Customer Success Stories

De-Risking the Pipeline

MMR

Fostering Health Equity in Multiple Myeloma Research

Multiple myeloma is the most common hematologic malignancy among Black & African Americans.1 However, they comprise only 4% of enrollees in clinical trials supporting FDA approval of multiple myeloma drugs.2 Acclinate collaborated with the Multiple Myeloma Research Foundation (MMRF) from April to October 2024 to address this disparity and support more representative research.

Read Case Study

83%-95%

of attendees felt comfortable participating in discussions about their health

9.6%-62%

reported limited knowledge of clinical trials before the events

32.3%-83%

felt more informed about clinical research after these events